Recon: Eli Lilly to buy biotech Orna for up to $2.4B; Novo sues Hims to stop obesity drug copycats

• TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics (STAT)
• Lawsuit against Hims & Hers should be ‘wake-up call’ for compounders, Novo chief counsel says (STAT)
• Hims & Hers will stop selling compounded version of Novo’s obesity pill (STAT)
• How the Centers for Medicare and Medicaid Services became the shining light of Trump’s second term (STAT)
• FDA commissioner pledges crackdown on compounding practices (Fierce Pharma)

• India's Aurobindo Pharma posts higher profit on steady domestic demand (Reuters)
• Dsm-firmenich agrees sale of animal health unit, $2.6 billion price tag disappoints (Reuters)
• Editor’s Corner: Pharma's slack tightening across pipelines, trust (Fierce Pharma)
• EU AI Act Could ‘Set Back’ Benefits Of AI In Drug Development If Applied To R&D (Pink Sheet)
• US-India Trade Deal : Generics Dance Goes On, Oil Prices To Be Watched (Pink Sheet)
• EU CHMP Opinions And MAA Updates (Pink Sheet)
• EU food agency sets 'safe' consumption level for hemp-derived CBD (Reuters)

• Biotech doubles financing in quest to silence genes behind neurological diseases (STAT)
• Eli Lilly to buy Orna Therapeutics for $2.4 billion (STAT)
• Takeda deepens AI drug discovery push with $1.7 billion Iambic deal (Reuters)
• Lilly Inks Deal with Innovent to Speed Up Early Drug Development (Bloomberg)
• Lilly likens relentless work of scientific and athletic progress in Winter Olympics ad (Fierce Pharma)
• Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals (Fierce Pharma)
• Biogen pins SMA recovery on high-dose Spinraza amid projected 2026 revenue slump (Fierce Pharma)

• Abbott Says Plans To Launch Dual Diabetes Sensor Unimpeded By Latest Warning Letter (MedTech Insight)
• Boston Scientific Sees EP Growth Exceeding Market Despite PFA Competition (MedTech Insight)
• Boston Scientific Says Penumbra Deal Could Lift Market Growth Profile As 10%+ Organic Target Holds (MedTech Insight)
• Bundling Approach Brings $382M Antitrust Verdict Against Medtronic (MedTech Insight)

• Texas plant-based meat labeling law struck down by court (Food Dive)
• Congresswoman says promises are not enough to allow Boar's Head to reopen facility (Food Safety News)

• Federal government turns to fresher data to rein in Medicare Advantage upcoding (STAT)
• As a scientist and NFL widow, I am furious about a recent NFL Players Association-funded CTE study (STAT)
• Faster FDA Reviews Cut Red Tape, But Critics Wonder at What Cost (Bloomberg)
• Sixth Circuit Affirms Steep Sentence in FDC Act Counterfeiting Case (FDA Law Blog)
• Following legal setbacks, HHS agrees to toss 340B Rebate Model Pilot Program (Fierce Pharma)
• Citizen Pazdur: Former US FDA Oncology Head Still Interested In Drug Development (Pink Sheet)